Display Settings:

Format

Send to:

Choose Destination
    Antivir Ther. 2009;14(2):143-54.

    Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response.

    Source

    JW Goethe University Hospital, Frankfurt, Germany.

    Abstract

    Current guidelines recommend a full 24-week regimen for all patients undergoing treatment for genotype 2 or 3 hepatitis C virus (HCV) infection. Recent data from two large randomized studies, one with pegylated interferon-alpha2a plus ribavirin (RBV) and one with pegylated interferon-alpha2b plus RBV assessed treatment duration and on-treatment predictors, such as rapid virological response (RVR; HCV RNA <50 IU/ml at week 4) or sustained virological response rates. Overall, these studies have shown that abbreviated regimens are generally less effective than standard 24-week regimens in genotype 2 or 3 patients because of a higher rate of relapse. However, abbreviated treatment might be offered to selected patients with an RVR provided that they have a low baseline viral load and minimal hepatic fibrosis.

    PMID:
    19430089
    [PubMed - indexed for MEDLINE]

    LinkOut - more resources

    Other Literature Sources

    Molecular Biology Databases

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk